Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TK2 | O00142 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4662853 | 0.73 | CRBN (0.52) | TYMPSMN1; SMN2 | |
| SCHEMBL7834516 | 0.73 | HPGD (0.54) | MAPK1HPGDTK1TK2SMN1; SMN2 | |
| SCHEMBL4219701 | 0.71 | ALDH1A1 (0.53) | HPGDTYMPLMNASMN1; SMN2 | |
| SCHEMBL22263564 | 0.71 | MAPK1 (0.40) | MAPK1HPGDTK1LMNATK2 | |
| SCHEMBL7832165 | 0.71 | MAPK1 (0.61) | MAPK1HPGDTK1 | |
| SCHEMBL7833356 | 0.70 | PKM (0.42) | MAPK1HPGDLMNATK2SMN1; SMN2 | |
| SCHEMBL11738105 | 0.68 | ERCC1 (0.38) | MAPK1HPGDTYMPLMNASMN1; SMN2 | |
| SCHEMBL15688187 | 0.68 | MAPK1 (0.46) | MAPK1HPGDTK1TK2SMN1; SMN2 | |
| SCHEMBL15345004 | 0.68 | MAPT (0.53) | MAPK1HPGDLMNASMN1; SMN2 | |
| SCHEMBL20577849 | 0.68 | ATM (0.48) | MAPK1HPGDTK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124417-B2 | Method for analyzing nucleobases on a single molecular basis | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20090155917-A1 | Method for analyzing nucleobases on a single molecular basis | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1841883-A4 | A METHOD FOR ANALYZING NUCLEOBASES ON A SINGLE MOLECULAR BASIS | JAPAN SCIENCE & TECH AGENCY (JP) | 2009-02-25 | — | — | EP | disclosed |
| EP-1841883-A1 | A METHOD FOR ANALYZING NUCLEOBASES ON A SINGLE MOLECULAR BASIS | Japan Science and Technology Agency (JP) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006070946-A1 | A METHOD FOR ANALYZING NUCLEOBASES ON A SINGLE MOLECULAR BASIS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-07-06 | — | — | WO | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155917-A1 | Method for analyzing nucleobases on a single molecular basis | NT5C3B, NT5C2, SAMHD1 | MAPK1 3338/4885HPGD 4253/4885TYMP 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.